PYXS Stock Price, Pyxis Oncology, Inc. Quote, Chart

Market Summary

USD4.41+0.01

Market Closed

0.23%

PYXS Stock Price

View Fullscreen

PYXS RSI Chart

PYXS Valuation

Market Cap

255.8M

Price/Earnings (Trailing)

-3.47

Price/Sales (Trailing)

37.36

Price/Free Cashflow

-3.3

PYXS Price/Sales (Trailing)

PYXS Profitability

Return on Equity

-58.7%

Return on Assets

-42.47%

Free Cashflow Yield

-30.27%

PYXS Fundamentals

PYXS Revenue

Revenue (TTM)

6.8M

Rev. Growth (Yr)

-14.85%

Rev. Growth (Qtr)

-6.62%

PYXS Earnings

Earnings (TTM)

-73.8M

Earnings Growth (Yr)

56.8%

Earnings Growth (Qtr)

32.33%

Breaking Down PYXS Revenue

Last 7 days

2.3%

Last 30 days

-18.2%

Last 90 days

19.6%

Trailing 12 Months

50.2%

How does PYXS drawdown profile look like?

PYXS Financial Health

Current Ratio

4.84

PYXS Investor Care

Shares Dilution (1Y)

135.81%

Diluted EPS (TTM)

-1.85

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q3	Q4
2023	4.4M	6.0M	6.8M
2022	1.0M	1.9M	2.8M
2021	0	0	181.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Pyxis Oncology, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 26, 2024	humphrey rachel	acquired	-	-	38,741	-
Mar 26, 2024	cline darren s	acquired	-	-	35,219	-
Mar 26, 2024	dupont jakob	acquired	-	-	38,741	-
Mar 26, 2024	wadhane jitendra	acquired	-	-	131,484	svp, chief accounting officer
Mar 26, 2024	connealy pamela ann	acquired	-	-	328,710	cfo & coo
Mar 26, 2024	flavin john l	acquired	-	-	35,219	-
Mar 26, 2024	lewis-hall freda c	acquired	-	-	35,219	-
Nov 29, 2023	connealy pamela ann	sold (taxes)	-51,728	1.4	-36,949	cfo and coo
Nov 15, 2023	wadhane jitendra	acquired	-	-	40,000	chief accounting officer
Sep 28, 2023	connealy pamela ann	bought	14,960	1.87	8,000	cfo and coo

Which funds bought or sold PYXS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	SCHULHOFF & CO INC	unchanged	-	54,120	93,720	0.04%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 29, 2024	COMMONWEALTH EQUITY SERVICES, LLC	added	133	106,000	129,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	added	904	661,538	690,580	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	492	852	-%
Apr 24, 2024	West Branch Capital LLC	unchanged	-	62.00	107	-%
Apr 23, 2024	Gradient Investments LLC	sold off	-100	-2.00	-	-%
Apr 17, 2024	Coston, McIsaac & Partners	unchanged	-	-	-	-%
Apr 15, 2024	UNIVERSITY OF CHICAGO	unchanged	-	119,878	207,594	0.30%
Mar 11, 2024	VANGUARD GROUP INC	added	14.6	82,949	2,352,030	-%

Are Funds Buying or Selling PYXS?

Are funds buying PYXS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PYXS

No. of Funds

Unveiling Pyxis Oncology, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 03, 2024	sullivan lara	8.89%	5,489,699	SC 13D/A
Mar 08, 2024	deep track capital, lp	7.87%	4,184,100	SC 13G
Feb 14, 2024	biotechnology value fund l p	-	0	SC 13G/A
Feb 14, 2024	tang capital partners lp	0.0%	0	SC 13G/A
Jan 26, 2024	ridgeback capital investments l.p.	9.8%	4,345,228	SC 13G
Apr 04, 2023	sullivan lara	10.2%	4,170,274	SC 13D/A
Mar 23, 2023	pfizer inc	2.92%	0	SC 13G/A
Feb 14, 2023	rtw investments, lp	0%	0	SC 13G/A
Feb 14, 2023	biotechnology value fund l p	4.5%	1,585,000	SC 13G/A
Feb 14, 2023	ra capital management, l.p.	0%	0	SC 13G/A

Recent SEC filings of Pyxis Oncology, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 04, 2024	424B2	Prospectus Filed
Apr 03, 2024	EFFECT	EFFECT
Apr 03, 2024	SC 13D/A	13D - Major Acquisition
Apr 01, 2024	CORRESP	CORRESP
Mar 29, 2024	UPLOAD	UPLOAD
Mar 28, 2024	4	Insider Trading
Mar 28, 2024	4	Insider Trading

Peers (Alternatives to Pyxis Oncology, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Pyxis Oncology, Inc. News

Latest updates

Pyxis Oncology, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)									(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q1	2021Q4	2021Q3	2021Q2
Revenue	-6.6%	1,594	1,707	1,673	1,872	719	585	450	316	181
Operating Expenses	-0.9%	25,136	25,354	6,216	49,121	28,393	9,094	-24,334	11,621	5,941
S&GA Expenses	-15.2%	9,047	10,667	3,279	8,119	9,359	1,986	-2,170	3,772	2,736
R&D Expenses	9.5%	16,089	14,687	2,937	36,336	19,034	7,108	-22,164	7,849	3,205
Income Taxes	-	-	-	20.00	-	-	-	-	-	-
Net Income	32.3%	-15,597	-23,049	-19,243	-36,101	-27,674	-31,380	30,230	-14,175	-8,146
Net Income Margin	-1039.9%	-10.78*	-0.95*	-4.56*	-11.60*	-28.58*	-22.52*	-159.76*	-	-
Free Cashflow	13.5%	-15,254	-17,644	-6,762	45,739	-24,823	-8,383	-259	-7,288	2,491

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-6.9%	174	187	175	18.00	211	224	243	253	39.00	139	10.00
Current Assets	-10.4%	125	139	149	17.00	187	203	227	251	38.00	134	8.00
Cash Equivalents	-34.3%	10.00	15.00	26.00	13.00	179	199	223	247	23.00	133	8.00
Net PPE	-2.5%	12.00	12.00	13.00	-	11.00	6.00	1.00	1.00	0.00	1.00	1.00
Liabilities	-1.5%	48.00	49.00	30.00	14.00	51.00	35.00	31.00	19.00	17.00	17.00	4.00
Current Liabilities	-9.1%	26.00	28.00	9.00	14.00	32.00	19.00	15.00	19.00	17.00	17.00	4.00
Shareholder's Equity	-8.9%	126	138	145	152	161	189	212	234	261	-	50.00
Retained Earnings	-5.8%	-286	-270	-247	-182	-212	-176	-148	-123	-144	-74.89	-15.74
Additional Paid-In Capital	0.8%	412	409	393	186	373	365	361	357	167	3.00	0.00
Shares Outstanding	1.0%	45.00	44.00	39.00	25.00	35.00	32.00	32.00	18.00	18.00	1.00	1.00
Float	-	-	-	97.00	-	-	-	77.00	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	13.2%	-15,254	-17,583	-31,110	-6,762	-17,387	-20,557	-43,051	-8,340	-745	-7,288	2,862	-18,731	-	-
Share Based Compensation	-37.9%	3,215	5,179	8,066	486	3,898	4,449	6,996	421	-2,186	307	572	2,450	-	-
Cashflow From Investing	55.7%	10,228	6,571	-123,798	2,150	-1,858	-4,266	-2,795	2,520	22,614	-	-371	-219	-	-
Cashflow From Financing	85.4%	-25.00	-171	3,585	2,540	-	6.00	249	-72.00	-149,107	-1,708	-682	151,534	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PYXS Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development expense	$ 49,586	$ 86,129
General and administrative	32,610	37,352
Total operating expenses	82,196	123,481
Loss from operations	(82,196)	(123,481)
Other income, net:
Interest and investment income	6,630	2,764
Sublease income	1,776
Total other income, net	8,406	2,764
Net loss	$ (73,790)	$ (120,717)
Net loss per common share - basic	$ (1.85)	$ (3.65)
Net loss per common share - diluted	$ (1.85)	$ (3.65)
Weighted average shares of common stock outstanding - basic	39,904,603	33,033,081
Weighted average shares of common stock outstanding - diluted	39,904,603	33,033,081
Other comprehensive income:
Net unrealized gain on marketable debt securities	$ 63
Other comprehensive income	63
Comprehensive loss	$ (73,727)	$ (120,717)

PYXS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 9,664	$ 179,293
Marketable debt securities, short-term	109,634
Restricted cash	1,472	1,472
Prepaid expenses and other current assets	3,834	5,847
Total current assets	124,604	186,612
Property and equipment, net	11,872	11,165
Intangible assets, net	24,308
Operating lease right-of-use assets	12,942	13,602
Total assets	173,726	211,379
Current liabilities:
Accounts payable	3,896	7,097
Accrued expenses and other current liabilities	12,971	24,537
Operating lease liabilities, current portion	1,232
Deferred revenue	7,660
Total current liabilities	25,759	31,634
Operating lease liabilities, net of current portion	20,099	18,921
Deferred tax liability, net	2,164
Total liabilities	48,022	50,555
Commitments and contingencies (Note 19)
Stockholders' equity:
Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; zero shares issued and outstanding
Common stock, $0.001 par value per share; 190,000,000 shares authorized; 44,754,853 and 35,110,016 shares issued as of December 31, 2023 and 2022, respectively, 44,754,853 and 34,958,730 shares outstanding as of December 31, 2023 and 2022, respectively	45	34
Additional paid-in capital	411,821	373,225
Accumulated other comprehensive income	63
Accumulated deficit	(286,225)	(212,435)
Total stockholders' equity	125,704	160,824
Total liabilities and stockholders' equity	$ 173,726	$ 211,379

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Lara S. Sullivan M.D., MBA
WEBSITE	https://pyxisoncology.com
INDUSTRY	Biotechnology
EMPLOYEES	72

Pyxis Oncology, Inc. Frequently Asked Questions

What is the ticker symbol for Pyxis Oncology, Inc.? What does PYXS stand for in stocks?

PYXS is the stock ticker symbol of Pyxis Oncology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pyxis Oncology, Inc. (PYXS)?

As of Thu May 02 2024, market cap of Pyxis Oncology, Inc. is 255.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PYXS stock?

You can check PYXS's fair value in chart for subscribers.

What is the fair value of PYXS stock?

You can check PYXS's fair value in chart for subscribers. The fair value of Pyxis Oncology, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pyxis Oncology, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PYXS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pyxis Oncology, Inc. a good stock to buy?

The fair value guage provides a quick view whether PYXS is over valued or under valued. Whether Pyxis Oncology, Inc. is cheap or expensive depends on the assumptions which impact Pyxis Oncology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PYXS.

What is Pyxis Oncology, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, PYXS's PE ratio (Price to Earnings) is -3.47 and Price to Sales (PS) ratio is 37.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PYXS PE ratio will change depending on the future growth rate expectations of investors.